Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Arch Pathol Lab Med Retrieve available abstracts of 46 articles: HTML format Text format

Single Articles

June 2018
1. LUK PP, Selinger CI, Mahar A, Cooper WA, et al
   Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
   Arch Pathol Lab Med. 2018 Jun 14. doi: 10.5858/arpa.2017-0502.
   PubMed     Text format     Abstract available
   
   
   April 2018
2. SAXENA A
   Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients with Targetable Mutations Following Disease Progression.
   Arch Pathol Lab Med. 2018 Apr 12. doi: 10.5858/arpa.2018-0111.
   PubMed     Text format    
   
   
   
3. PLANCHARD D, Johnson BE
   BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.
   Arch Pathol Lab Med. 2018 Apr 12. doi: 10.5858/arpa.2018-0088.
   PubMed     Text format    
   
   
   
4. HALMOS B
   Molecular Testing in Lung Cancer: Where to Draw the Line?
   Arch Pathol Lab Med. 2018 Apr 6. doi: 10.5858/arpa.2018-0060.
   PubMed     Text format    
   
   
   
5. ALTORKI NK
   Molecular Testing for Early Lung Cancer.
   Arch Pathol Lab Med. 2018 Apr 6. doi: 10.5858/arpa.2018-0087.
   PubMed     Text format    
   
   
   March 2018
6. AISNER DL
   The Revised College of American Pathologists/International Association for the Study of Lung Cancer Guidelines/Association for Molecular Pathology: A Step Forward for Molecular Cytopathology.
   Arch Pathol Lab Med. 2018 Mar 29. doi: 10.5858/arpa.2018-0081.
   PubMed     Text format    
   
   
   
7. JAIN D, Roy-Chowdhuri S
   Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review.
   Arch Pathol Lab Med. 2018 Mar 16. doi: 10.5858/arpa.2017-0444.
   PubMed     Text format     Abstract available
   
   
   
8. LOZANO MD, Echeveste JI, Abengozar M, Mejias LD, et al
   Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less.
   Arch Pathol Lab Med. 2018;142:291-298.
   PubMed     Text format     Abstract available
   
   
   February 2018
9. DEL C MONROIG-BOSQUE P, Driver B, Morales-Rosado JA, Deavers M, et al
   Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
   Arch Pathol Lab Med. 2018 Feb 12. doi: 10.5858/arpa.2017-0516.
   PubMed     Text format     Abstract available
   
   
   January 2018
10. DOXTADER EE, Cheng YW, Zhang Y
    Molecular Testing of Non-Small Cell Lung Carcinoma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Fine-Needle Aspiration.
    Arch Pathol Lab Med. 2018 Jan 26. doi: 10.5858/arpa.2017-0184.
    PubMed     Text format     Abstract available
    
    
    
11. LINDEMAN NI, Cagle PT, Aisner DL, Arcila ME, et al
    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and
    Arch Pathol Lab Med. 2018 Jan 22. doi: 10.5858/arpa.2017-0388.
    PubMed     Text format     Abstract available
    
    
    
12. WALTS AE, Marchevsky AM
    Current Evidence Does Not Warrant Frozen Section Evaluation for the Presence of Tumor Spread Through Alveolar Spaces.
    Arch Pathol Lab Med. 2018;142:59-63.
    PubMed     Text format     Abstract available
    
    
    
13. HUSAIN AN, Colby TV, Ordonez NG, Allen TC, et al
    Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
    Arch Pathol Lab Med. 2018;142:89-108.
    PubMed     Text format     Abstract available
    
    
    December 2017
14. MEHRAD M, Roy S, Bittar HT, Dacic S, et al
    Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations.
    Arch Pathol Lab Med. 2017 Dec 8. doi: 10.5858/arpa.2017-0046.
    PubMed     Text format     Abstract available
    
    
    November 2017
15. DRIVER BR, Miller RA, Miller T, Deavers M, et al
    Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Arch Pathol Lab Med. 2017;141:1529-1532.
    PubMed     Text format     Abstract available
    
    
    September 2017
16. WOO JS, Reddy OL, Koo M, Xiong Y, et al
    Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms.
    Arch Pathol Lab Med. 2017;141:1195-1213.
    PubMed     Text format     Abstract available
    
    
    August 2017
17. PENG Y, Butt YM, Chen B, Zhang X, et al
    Update on Immunohistochemical Analysis in Breast Lesions.
    Arch Pathol Lab Med. 2017;141:1033-1051.
    PubMed     Text format     Abstract available
    
    
    July 2017
18. WANG X, Gao Y, Wang B, Zhang Z, et al
    Analytic and Clinical Validation of an Ultrasensitive, Quantitative Polymerase Chain Reaction Assay for EGFR Mutation Analysis With Circulating Tumor DNA.
    Arch Pathol Lab Med. 2017;141:978-984.
    PubMed     Text format     Abstract available
    
    
    June 2017
19. JAIN D, Allen TC, Aisner DL, Beasley MB, et al
    Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.
    Arch Pathol Lab Med. 2017 Jun 22. doi: 10.5858/arpa.2017-0114.
    PubMed     Text format     Abstract available
    
    
    December 2016
20. BAHAMON BN, Gao F, Danaee H
    Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.
    Arch Pathol Lab Med. 2016;140:1397-1403.
    PubMed     Text format     Abstract available
    
    
    November 2016
21. DACIC S
    Lung Carcinoma Staging Update.
    Arch Pathol Lab Med. 2016.
    PubMed     Text format     Abstract available
    
    
    
22. DOLLED-FILHART M, Locke D, Murphy T, Lynch F, et al
    Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
    Arch Pathol Lab Med. 2016;140:1259-1266.
    PubMed     Text format     Abstract available
    
    
    October 2016
23. PADMANABHAN V, Steinmetz HB, Rizzo EJ, Erskine AJ, et al
    Improving Adequacy of Small Biopsy and Fine-Needle Aspiration Specimens for Molecular Testing by Next-Generation Sequencing in Patients With Lung Cancer: A Quality Improvement Study at Dartmouth-Hitchcock Medical Center.
    Arch Pathol Lab Med. 2016.
    PubMed     Text format     Abstract available
    
    
    
24. ZAKOWSKI MF, Rekhtman N, Auger M, Booth CN, et al
    Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.
    Arch Pathol Lab Med. 2016;140:1116-20.
    PubMed     Text format     Abstract available
    
    
    
25. CHURG A, Attanoos R, Borczuk AC, Chirieac LR, et al
    Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
    Arch Pathol Lab Med. 2016;140:1104-10.
    PubMed     Text format     Abstract available
    
    
    September 2016
26. ZHOU F, Moreira AL
    Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
    Arch Pathol Lab Med. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
27. DOLLED-FILHART M, Roach C, Toland G, Stanforth D, et al
    Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
    Arch Pathol Lab Med. 2016.
    PubMed     Text format     Abstract available
    
    
    
28. MILLER RA, Cagle PT, Bernicker EH
    First-Line Immune Therapy-Implications for Pathologists.
    Arch Pathol Lab Med. 2016;140:739-40.
    PubMed     Text format    
    
    
    May 2016
29. SHOLL LM, Aisner DL, Allen TC, Beasley MB, et al
    Liquid Biopsy in Lung Cancer.
    Arch Pathol Lab Med. 2016.
    PubMed     Text format     Abstract available
    
    
    April 2016
30. ROY-CHOWDHURI S, Aisner DL, Allen TC, Beasley MB, et al
    Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society.
    Arch Pathol Lab Med. 2016.
    PubMed     Text format     Abstract available
    
    
    
31. SAUTER JL, Butnor KJ
    Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertia
    Arch Pathol Lab Med. 2016;140:358-61.
    PubMed     Text format     Abstract available
    
    
    
32. CAGLE PT, Allen TC, Bernicker EH, Ge Y, et al
    Impact of Recent Developments in Lung Cancer on the Practice of Pathology.
    Arch Pathol Lab Med. 2016;140:322-5.
    PubMed     Text format     Abstract available
    
    
    
33. SHI J, Liu H, Ma XJ, Chen Z, et al
    Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas.
    Arch Pathol Lab Med. 2016;140:332-40.
    PubMed     Text format     Abstract available
    
    
    
34. SHOLL LM, Aisner DL, Allen TC, Beasley MB, et al
    Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
    Arch Pathol Lab Med. 2016;140:341-4.
    PubMed     Text format     Abstract available
    
    
    
35. KERR KM, Hirsch FR
    Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
    Arch Pathol Lab Med. 2016;140:326-31.
    PubMed     Text format     Abstract available
    
    
    
36. DRIVER BR, Portier BP, Mody DR, Deavers M, et al
    Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Arch Pathol Lab Med. 2016;140:312-7.
    PubMed     Text format     Abstract available
    
    
    March 2016
37. KERR KM, Nicolson MC
    Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Arch Pathol Lab Med. 2016;140:249-54.
    PubMed     Text format     Abstract available
    
    
    
38. BERNICKER E
    Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective.
    Arch Pathol Lab Med. 2016;140:245-8.
    PubMed     Text format     Abstract available
    
    
    
39. THUNNISSEN E, Blaauwgeers HJ, de Cuba EM, Yick CY, et al
    Ex Vivo Artifacts and Histopathologic Pitfalls in the Lung.
    Arch Pathol Lab Med. 2016;140:212-20.
    PubMed     Text format     Abstract available
    
    
    January 2016
40. BORCZUK AC, Allen TC
    PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?
    Arch Pathol Lab Med. 2016.
    PubMed     Text format     Abstract available
    
    
    December 2015
41. CAGLE PT, Bernicker EH
    Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
    Arch Pathol Lab Med. 2015;139:1477-8.
    PubMed     Text format    
    
    
    November 2015
42. CAGLE PT, Bernicker EH
    A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.
    Arch Pathol Lab Med. 2015;139:1329.
    PubMed     Text format    
    
    
    October 2015
43. LAGSTEIN A
    Pulmonary Apical Cap-What's Old Is New Again.
    Arch Pathol Lab Med. 2015;139:1258-62.
    PubMed     Text format     Abstract available
    
    
    
44. PANG JC, Roh MH
    Metastases to the Pancreas Encountered on Endoscopic Ultrasound-Guided, Fine-Needle Aspiration.
    Arch Pathol Lab Med. 2015;139:1248-52.
    PubMed     Text format     Abstract available
    
    
    September 2015
45. VOLMAR KE, Idowu MO, Souers RJ, Nakhleh RE, et al
    Molecular Testing in Anatomic Pathology and Adherence to Guidelines: A College of American Pathologists Q-Probes Study of 2230 Testing Events Reported by 26 Institutions.
    Arch Pathol Lab Med. 2015;139:1115-24.
    PubMed     Text format     Abstract available
    
    
    
46. LI X, Brownlee NA, Sporn TA, Mahar A, et al
    Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases.
    Arch Pathol Lab Med. 2015;139:1129-36.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: